Y-mAbs Therapeutics Inc (NASDAQ:YMAB), a commercial-stage biopharmaceutical company, has recently witnessed a significant insider purchase that has caught the attention of investors and market analysts alike.
Y-mAbs Therapeutics Inc (NASDAQ:YMAB), a commercial-stage biopharmaceutical company, has recently witnessed a significant insider purchase that has caught the attention of investors and market analysts alike.
In the realm of investment, insider transactions hold a significant place as they can provide insights into a company's internal perspective on its financial health and future prospects.
In a notable insider transaction, Director Timothy Christen has recently increased his stake in Expensify Inc (NASDAQ:EXFY) by purchasing 47,050 shares of the company's stock.